Cargando…
Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
The development of an efficacious vaccine against norovirus is of paramount importance given its potential to reduce the global burden of norovirus-associated morbidity and mortality. Here, we report a detailed immunological analysis of a phase I, double-blind, placebo-controlled clinical trial perf...
Autores principales: | Waerlop, Gwenn, Janssens, Yorick, Jacobs, Bart, Jarczowski, Franziska, Diessner, André, Leroux-Roels, Geert, Klimyuk, Victor, Leroux-Roels, Isabel, Thieme, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331465/ https://www.ncbi.nlm.nih.gov/pubmed/37435073 http://dx.doi.org/10.3389/fimmu.2023.1188431 |
Ejemplares similares
-
A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2022) -
The role of cell-mediated immunity against influenza and its implications for vaccine evaluation
por: Janssens, Yorick, et al.
Publicado: (2022) -
GII.P16-GII.2 Recombinant Norovirus VLPs Polarize Macrophages Into the M1 Phenotype for Th1 Immune Responses
por: Han, Ji Cheng, et al.
Publicado: (2021) -
Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4(+) T cell immunity within the FLUCOP consortium
por: Begue, Sarah, et al.
Publicado: (2022) -
Norovirus waterborne outbreak in Chalkidiki, Greece, 2015: detection of GI.P2_GI.2 and GII.P16_GII.13 unusual strains
por: Tryfinopoulou, K., et al.
Publicado: (2019)